Acadia Pharmaceuticals Obtains Preliminary Approval for Governance Settlement

Acadia Pharmaceuticals received preliminary court approval for a settlement in a stockholder derivative action. This agreement mandates four years of corporate governance and clinical-trial oversight reforms instead of providing cash payouts to shareholders.

The United States District Court for the Southern District of California granted preliminary approval on August 24, 2026, for the settlement in Kanner et al. v. Biggar et al., Case No. 3:23-cv-02293-WQH-MSB. Securities class actions typically aim to compensate investors for financial losses, but this derivative suit focuses on internal corporate practices and executive accountability.

What the Settlement Mandates

Under the terms of the proposed settlement, Acadia Pharmaceuticals will implement internal controls. These reforms address concerns regarding the company's clinical-trial data reporting and its communications with the U.S. Food and Drug Administration (FDA).

The agreement requires the company to maintain these governance enhancements for four years. The reforms include:

• Enhanced oversight of clinical-trial data integrity.
• Stricter protocols for FDA communication and regulatory filings.
• Formalized insider trading policies.
• Increased executive accountability measures regarding project reporting.

Legal Fees and Final Approval

Shareholders will not receive direct monetary compensation from the settlement. The parties agreed that the company will pay $1.5 million in legal fees and expenses to the plaintiffs' attorneys, pending final court approval. The court may authorize service awards of up to $5,000 for each of the named plaintiffs from this total amount.

Stockholders who wish to contest the terms of the settlement must submit their objections to the court by December 23, 2026. The federal court will hold a hearing to consider final approval of the agreement on January 13, 2027.

Understanding Derivative Actions

A stockholder derivative action is a lawsuit brought by a shareholder on behalf of a corporation against its directors or officers. The claim belongs to the company rather than the individual shareholder. Consequently, remedies such as the governance reforms mandated here are directed at improving company operations and oversight. These settlements are used to force structural changes within a firm's board or management committees when internal governance is perceived to have failed.